Celltrion Pharmaceuticals has scheduled a symposium on March 18-19 to present and discuss the benefits of their Donerion Patch (ingredient name: donepezil) to neurologists.
The symposium will take place in Jeju Island and will consist of four sessions covering topics such as the phase 3 clinical trial and case review of Donerion Patch, social cognition in neurodegenerative disease, updates on the results of recently announced amyloid-based monoclonal antibody trials, and updates on biomarker-guided diagnosis in Alzheimer's disease.
Donerion Patch was launched in Korea in August 2022 after receiving approval from the Ministry of Food and Drug Safety in November 2021. Unlike conventional oral medications, Donerion Patch is applied twice a week, increasing medication compliance for dementia patients and convenience for their caregivers.
Korean Alzheimer's disease treatment market was worth approximately KRW 340 billion based on sales last year, with donepezil accounting for KRW 260 billion, or 77%, according to market research institute UBIST. With the aging population leading to a rise in dementia patients, the treatment market is expected to expand rapidly.
“Through this symposium, we plan to provide a venue for academic exchange among neurologists, while actively promoting the advantages and effectiveness of the Donerion patch as a new treatment option in the Alzheimer’s disease treatment market,” said an official from Celltrion Pharmaceuticals. "We will do our best to strengthen accessibility and supply products so that you can use this Donerion Patch.”
